|
| Status |
Public on Oct 22, 2012 |
| Title |
Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer [RPPA-SKBR3] |
| Organism |
Homo sapiens |
| Experiment type |
Protein profiling by protein array
|
| Summary |
EGFR-inhibition is required for targeted therapies of ERBB2-positive/EGFR high breast cancer.
Approximately 30% of human ERBB2-positive breast tumors also express EGFR.
|
| |
|
| Overall design |
Three targeted therapeutics (erlotinib, pertuzumab, trastuzumab) and two ligands (EGF, HRG) were analyzed in all possible combinations. Each experiment involving inhibition with targeted drugs was performed in three, and measurements without inhibitors were performed in five biological replicates. This resulted in 780 samples. HRG stimulated cells under the triple drug combination exceptionally have two biological replicates. Incubation with therapeutics only and dilution series of control lysated were included as controls.
|
| |
|
| Contributor(s) |
Henjes F, Bender C, von der Heyde S, Braun L, Mannsperger HA, Schmidt C, Wiemann S, Hasmann M, Aulmann S, Beissbarth T, Korf U |
| Citation(s) |
23552733 |
| |
| Submission date |
Mar 07, 2012 |
| Last update date |
Aug 15, 2014 |
| Contact name |
Ulrike Korf |
| E-mail(s) |
u.korf@dkfz.de
|
| Phone |
0049 (0) 6221 424765
|
| Fax |
0049 (0) 6221 423454
|
| Organization name |
German Cancer Research Center
|
| Department |
Molecular Genome Analysis
|
| Street address |
Im Neuenheimer Feld 580
|
| City |
Heidelberg |
| ZIP/Postal code |
69120 |
| Country |
Germany |
| |
|
| Platforms (1) |
| GPL15319 |
Targeted array-based proteomics [RPPA-SKBR3] |
|
| Samples (2) |
|
| This SubSeries is part of SuperSeries: |
| GSE36327 |
Targeted inhibition of human breast cancer cell lines selected as model systems of ERBB2-positive/EGFR high breast cancer |
|
| Relations |
| BioProject |
PRJNA155575 |
